Allena Pharmaceuticals, Inc. Accrued Expenses

Accrued Expenses of ALNA for past 10 years: annual, quarterly and twelve month trailing (TTM) including Accrued Expenses growth rates and interactive chart. Accrued expense is expense which has been incurred but not yet paid. Expense must be recorded in the accounting period in which it is incurred. Therefore, accrued expense must be recognized in the accounting period in which it occurs rather than in the following period in which it will be paid.


Highlights and Quick Summary

  • Accrued Expenses for the quarter ending March 31, 2022 was $1.69 Million (a -62.34% decrease compared to previous quarter)
  • Year-over-year quarterly Accrued Expenses decreased by -66.1%
  • Annual Accrued Expenses for 2021 was $4.48 Million (a 30.96% increase from previous year)
  • Annual Accrued Expenses for 2020 was $3.42 Million (a 1.51% increase from previous year)
  • Annual Accrued Expenses for 2019 was $3.37 Million (a -7.03% decrease from previous year)
Visit stockrow.com/ALNA for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Accrued Expenses of Allena Pharmaceuticals, Inc.

Most recent Accrued Expensesof ALNA including historical data for past 10 years.

Interactive Chart of Accrued Expenses of Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals, Inc. Accrued Expenses for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 $1.69
2021 $4.48 $4.35 $4.98 $3.62 $4.48
2020 $3.42 $2.54 $1.89 $1.86 $3.42
2019 $3.37 $3.37 $2.89 $2.67 $3.37
2018 $3.63 $3.16 $1.83 $1.22 $3.63
2017 $1.95 $2.16 $1.95
2016 $1.61
2015 $0.92 $0.93

Business Profile of Allena Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.